Re "Big Pharma means bigger costs" (Dan Morain, Sept. 29): Biosimilars have great potential, while also having manageable risks. Severe, untoward adverse allergic, aka "Immunogenicity" reactions are life-threatening conditions associated with these drug forms, even when cooperatively licensed. Treating them requires medical teams react quickly, and information on the specific drug form is crucial. Human and medical costs are high if this data isn't readily available.
Investments in safety should consider outcomes, particularly in key policy areas like biosimilars, as well as hospitals, nuclear power, road/traffic safety (e.g., car seats), and others. If even one loved one's life is saved because of shared pharmacist-MD biosimilar information as under SB598, it's worth it for society and its individual members. At present, we can't predict all cases of immunogenicity. Consequently, joint team communication on this critical aspect of preventive care is good patient safety policy; it's good public policy as well.
-- Bryan A. Liang, MD, PhD, JD, San Diego